Web22 gen 2024 · Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage III colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial. Web412P - Six-year updated results of Japan Clinical Oncology Group study (JCOG0910): Randomized phase III study of adjuvant chemotherapy with S-1 versus capecitabine in …
Randomized phase III study of adjuvant chemotherapy with S-1 …
Web18 mar 2024 · Background Adjuvant chemotherapy is an accepted treatment to improve survival rates in patients with stage III colon cancer, and regimens including oxaliplatin have been shown to be superior to those containing 5-FU alone. The purpose of this study was to examine the efficacy and feasibility of S-1 plus oxaliplatin (C-SOX) as adjuvant … WebObjectives: We conducted an open-label, multicenter, single-arm study to confirm the efficacy and safety of amrubicin (AMR), a topoisomerase II inhibitor, for treating … sunova koers
Capecitabine versus S-1 as adjuvant chemotherapy for patients …
Web2 feb 2024 · Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG, Smith AM, Heath RM, Brown JM ; MRC CLASICC trial group. Lancet, (9472):1718-1726 2005. http://www.jcog.jp/document/s_0910.pdf Web(JCOG0910),6 published in The Lancet Gastroenterology & Hepatology, shows that S1 is not noninferior to capecitabine in the adjuvant treatment of patients with resected stage III colorectal cancer. At the second preplanned interim analysis and after final accrual of 1564 patients, the observed hazard ratio for disease free sunova nz